Search

Displaying results 1531 - 1540 of 10000 in total
  1. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

    Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium
  2. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST

  3. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated … producers, and against non-enzymatic resistance mechanisms such as efflux and porin loss.

  4. Drug

    Mannitol

    go.drugbank.com/drugs/DB00742
    ApprovedInvestigational

    this indication under the name BRONCHITOL® by Chiesi USA Inc. … On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for

  5. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    [L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

  6. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. … A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period

  7. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    In general, the drug was well tolerated by patients during cardiac examinations [A32091]. … Its approval has been discontinued by the FDA. One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.

    Categories: X-Ray Contrast Activity, X-Ray Contrast Media, Iodinated
  8. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    It is a colorless, odorless, tasteless, non-toxic, inert, monatomic gas located at the top of the noble gases on the periodic table.

    Mixtures: Co-HE-O2-N2 Mixture
  9. Drug

    Quercus nigra pollen

    go.drugbank.com/drugs/DB10742
    Approved

    Quercus nigra pollen is the pollen of the Quercus nigra plant. Quercus nigra pollen is mainly used in allergenic testing.

    Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenCategories: Non-Standardized Pollen Allergenic Extract
  10. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc. … [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650]